| Chronic Lymphocytic Leukemia
Jaypirca vs Rituxan
Side-by-side clinical, coverage, and cost comparison for chronic lymphocytic leukemia.Deep comparison between: Jaypirca vs Rituxan with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRituxan has a higher rate of injection site reactions vs Jaypirca based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rituxan but not Jaypirca, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jaypirca
Rituxan
At A Glance
Oral
Once daily
BTK inhibitor
IV infusion
Anti-CD20 monoclonal antibody
Indications
- Mantle cell lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoma, Non-Hodgkin
- Chronic Lymphocytic Leukemia
- Rheumatoid Arthritis
- Granulomatosis with polyangiitis
- Microscopic Polyarteritis
- Pemphigus Vulgaris
- Acute lymphocytic leukemia
Dosing
Mantle cell lymphoma 200 mg orally once daily until disease progression or unacceptable toxicity; swallow tablets whole with water, with or without food.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 200 mg orally once daily until disease progression or unacceptable toxicity; swallow tablets whole with water, with or without food.
Lymphoma, Non-Hodgkin 375 mg/m2 IV; weekly for 4 or 8 doses for relapsed/refractory low-grade or follicular NHL; Day 1 of each chemotherapy cycle for up to 8 doses for previously untreated follicular or DLBCL; every 8 weeks for 12 doses as single-agent maintenance.
Acute lymphocytic leukemia 375 mg/m2 IV for 6 total infusions in combination with LMB chemotherapy (two doses during each of the two induction courses, one dose during each of the two consolidation courses) for pediatric patients aged 6 months and older.
Chronic Lymphocytic Leukemia 375 mg/m2 IV the day prior to initiation of cycle 1 FC chemotherapy, then 500 mg/m2 on Day 1 of cycles 2-6 every 28 days.
Rheumatoid Arthritis Two 1,000 mg IV infusions separated by 2 weeks per course in combination with methotrexate; subsequent courses every 24 weeks (no sooner than 16 weeks); premedicate with methylprednisolone 100 mg IV 30 minutes prior to each infusion.
Granulomatosis with polyangiitis, Microscopic Polyarteritis Induction: 375 mg/m2 IV once weekly for 4 weeks with glucocorticoids; follow-up: two 500 mg IV infusions separated by 2 weeks, then 500 mg IV every 6 months based on clinical evaluation.
Pemphigus Vulgaris Two 1,000 mg IV infusions separated by 2 weeks in combination with a tapering course of glucocorticoids; then 500 mg IV at Month 12 and every 6 months thereafter or based on clinical evaluation.
Contraindications
—
—
Adverse Reactions
Most common (>=30%) Decreased neutrophil count, decreased hemoglobin, decreased leukocytes, fatigue, decreased platelets, decreased lymphocyte count, calcium decreased
Serious Pneumonia, COVID-19, sepsis, febrile neutropenia, hemorrhage, pleural effusion
Most common (>=25%) Infusion-related reactions, fever, lymphopenia, chills, infection, asthenia (in NHL); infusion-related reactions, neutropenia (in CLL)
Serious Fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B reactivation with fulminant hepatitis, progressive multifocal leukoencephalopathy, tumor lysis syndrome, sepsis, cardiovascular events, renal toxicity, bowel obstruction and perforation
Postmarketing Prolonged pancytopenia, fatal cardiac failure, progressive multifocal leukoencephalopathy, severe mucocutaneous reactions, pyoderma gangrenosum, bowel obstruction and perforation, fatal bronchiolitis obliterans, fatal interstitial lung disease, posterior reversible encephalopathy syndrome
Pharmacology
Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK, a signaling protein of the B-cell antigen receptor and cytokine receptor pathways; it binds wild-type BTK and BTK harboring C481 mutations to inhibit BTK kinase activity and suppress malignant B-cell proliferation.
Rituximab is a chimeric murine/human IgG1 kappa monoclonal antibody that binds the CD20 antigen on pre-B and mature B-lymphocytes, mediating B-cell lysis via complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jaypirca
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Rituxan
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Jaypirca
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (1/8) · Qty limit (2/8)
Rituxan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Jaypirca
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Rituxan
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Chronic Lymphocytic Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Rituxan.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JaypircaView full Jaypirca profile
RituxanView full Rituxan profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.